Quadrosilan

Quadrosilan

File:Quadrosilan.svg
Clinical data
Trade names	Cisobitan
Other names	Quadrosilane; KABI-1774; 2,6-cisdiphenylhexa- methylcyclotetrasiloxane
Drug class	Nonsteroidal estrogen
Identifiers
IUPAC name 2,2,4,6,6,8-hexamethyl-4,8-diphenyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane
CAS Number	4657-20-9 checkY
PubChem CID	20774
ChemSpider	19557
UNII	MM48TFA73C
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H28O4Si4
Molar mass	420.758 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[Si]1(O[Si](O[Si](O[Si](O1)(C)C2=CC=CC=C2)(C)C)(C)C3=CC=CC=C3)C
InChI InChI=1S/C18H28O4Si4/c1-23(2)19-25(5,17-13-9-7-10-14-17)21-24(3,4)22-26(6,20-23)18-15-11-8-12-16-18/h7-16H,1-6H3 Key:ZTQZMPQJXABFNC-UHFFFAOYSA-N

Quadrosilan (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) (brand name Cisobitan; former developmental code name KABI-1774) is a synthetic nonsteroidal estrogen that was developed in the 1970s and that is or has been used as an antigonadotropic agent in the treatment of prostate cancer. It is an organosilicon compound, and is also known as 2,6-cisdiphenylhexamethylcyclotetrasiloxane. Quadrosilan has estrogenic activity equivalent to that of estradiol, and can produce feminization and gynecomastia as side effects in male patients.

See also

• Paroxypropione
• Metallibure